End-of-day quote
Shenzhen S.E.
23:00:00 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
13.24
CNY
|
+3.36%
|
|
+1.38%
|
-10.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,082
|
23,372
|
21,745
|
15,019
|
18,014
|
16,105
|
-
|
-
|
Enterprise Value (EV)
1 |
17,082
|
23,372
|
21,745
|
15,019
|
18,014
|
16,105
|
16,105
|
16,105
|
P/E ratio
|
22
x
|
24
x
|
76.6
x
|
81.7
x
|
-32.8
x
|
29.4
x
|
20.9
x
|
17.5
x
|
Yield
|
0.62%
|
0.26%
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.29
x
|
4.33
x
|
4.93
x
|
-
|
4.43
x
|
3
x
|
2.51
x
|
2.18
x
|
EV / Revenue
|
3.29
x
|
4.33
x
|
4.93
x
|
-
|
4.43
x
|
3
x
|
2.51
x
|
2.18
x
|
EV / EBITDA
|
-
|
-
|
53
x
|
-
|
-29
x
|
19.3
x
|
14.9
x
|
12.7
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.68
x
|
2.77
x
|
2.55
x
|
-
|
2.19
x
|
1.82
x
|
1.67
x
|
1.53
x
|
Nbr of stocks (in thousands)
|
1,051,198
|
1,234,677
|
1,234,106
|
1,226,025
|
1,218,803
|
1,216,390
|
-
|
-
|
Reference price
2 |
16.25
|
18.93
|
17.62
|
12.25
|
14.78
|
13.24
|
13.24
|
13.24
|
Announcement Date
|
27/02/20
|
30/03/21
|
12/04/22
|
14/04/23
|
19/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,187
|
5,400
|
4,409
|
-
|
4,068
|
5,367
|
6,413
|
7,377
|
EBITDA
1 |
-
|
-
|
410.2
|
-
|
-620.9
|
835
|
1,083
|
1,266
|
EBIT
1 |
1,076
|
1,085
|
212.2
|
-
|
-882.7
|
544.4
|
779.3
|
992.3
|
Operating Margin
|
20.75%
|
20.08%
|
4.81%
|
-
|
-21.7%
|
10.14%
|
12.15%
|
13.45%
|
Earnings before Tax (EBT)
1 |
1,068
|
1,081
|
210.8
|
-
|
-869
|
554.4
|
788
|
1,001
|
Net income
1 |
903.5
|
968.4
|
278.4
|
191.3
|
-551.1
|
550.6
|
774.1
|
929.9
|
Net margin
|
17.42%
|
17.93%
|
6.31%
|
-
|
-13.55%
|
10.26%
|
12.07%
|
12.61%
|
EPS
2 |
0.7400
|
0.7900
|
0.2300
|
0.1500
|
-0.4500
|
0.4500
|
0.6333
|
0.7567
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
0.1000
|
0.0500
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
30/03/21
|
12/04/22
|
14/04/23
|
19/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
12.8%
|
12.2%
|
3.28%
|
-
|
-6.35%
|
6.16%
|
7.99%
|
8.78%
|
ROA (Net income/ Total Assets)
|
8.67%
|
8.53%
|
-
|
-
|
-
|
4.7%
|
5.9%
|
6.5%
|
Assets
1 |
10,421
|
11,351
|
-
|
-
|
-
|
11,714
|
13,120
|
14,307
|
Book Value Per Share
2 |
6.060
|
6.840
|
6.920
|
-
|
6.750
|
7.290
|
7.910
|
8.640
|
Cash Flow per Share
2 |
0.7600
|
0.9000
|
0.2400
|
-
|
0.2800
|
0.0800
|
0.7700
|
0.3900
|
Capex
1 |
865
|
715
|
-
|
-
|
499
|
442
|
458
|
466
|
Capex / Sales
|
16.68%
|
13.24%
|
-
|
-
|
12.27%
|
8.23%
|
7.14%
|
6.31%
|
Announcement Date
|
27/02/20
|
30/03/21
|
12/04/22
|
14/04/23
|
19/04/24
|
-
|
-
|
-
|
Last Close Price
13.24
CNY Average target price
19
CNY Spread / Average Target +43.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.42% | 2.23B | | +19.98% | 43.48B | | +20.67% | 22.65B | | +14.56% | 14.73B | | +14.32% | 13.79B | | +44.72% | 12.04B | | -8.37% | 7.08B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.47B |
Generic Pharmaceuticals
|